¤K¤Q¤E¦~«×¤º¬ì±M¬ìÂå®v¦Ò¸Õµ§¸ÕÃD -- ¦Ò¥jÃD

(C) 1.¤@¦ì35·³°ü¤H¡A¦]·NÃѤ£²M³Q°e¨ì«æ¶E«Ç¡A²z¾ÇÀˬdÅã¥Ü¦³¤¤«×³h¦å¡A¥Ö½§¤W¦³»´·L·ï´³(purpura)¡AµL¨ä¥L¥X¦å²{¶H¡AµL§½³¡¯«¸g¾Ç²§±`¡C¦å²G¬Û¦p¤U¡G¦å¦â¯À 8.9 g/dL¡AWBC 12,900/£gL¡A¦å¤pªO30,000/£gL¡AµL¤£¥¿±`¥Õ¦å²y¡C¦å²G©Ù¤ù¦pªþ¹Ï¤T ¡A¾®¦åÀˬdµL²§±`¡C¦¹¯f¤H³Ì¥i¯àªº¶EÂ_¬°¦ó¡H
A.¯Sµo©Ê¦å¤pªO§C¤U©Êµµ´³(Idiopathic thrombocytopenic purpura)
B.¥ì¤Z¤ó¯g­Ô¸s(Evan syndrome)
C.®ê¶ë©Ê¦å¤pªO§C¤U©Êµµ´³(Thrombotic thrombocytopenic purpura)
D.¦A¥Í¤£¨}©Ê³h¦å(Aplastic anemia)
E.°©Åè¼W¥Í¤£¨}¯g­Ô¸s(Myelodysplastic syndrome)
 
(B) 2.¦³Ãö¤G¦yä²æ««(prolapse of mitral valve)ªº°O­z¡A¦óªÌ¨Ã¤£¥¿½T¡H
A.³o¬O¤@ºØ¨}©ÊªºÁ{§É¶EÂ_¡A¥H¶W­µªi¤ß¹Ï¤§²§±`²v¦b¦¨¤Hªº¤H¤f½Õ¬d°ª¹F5%¥H¤W
B.¥­½öÀˬd¸û©öÅ¥¥X¤ßÁY¤¤´ÁºVÀ»Án(mid-systolic click)¤Î¤ßÁYÂø­µ
C.¦³®a±Ú¦P¯f¶É¦V
D.¤ñ¤@¯ë¤H¦³¸û°ªªº¤ß¤º½¤ª¢µo¥Í
E.¬I¦æ¦UºØ¤â³NÀ³¦³¹w¨¾©Ê§Ü¥Í¯À¨Ï¥Î
 
(C) 3.¤U¦C¦óºØÃĪ«¤£À³¥Î¨ÓªvÀø­G»Ä°f¬y©Ê­¹¹Dª¢(reflux esophagitis)¡H
A.Antacids
B.H2-receptor antagonists
C.Anticholinergics
D.Metoclopramide
E.Omeprazole
 
(D) 4.¤U¦C¦óºØÀˬd¶µ¥Ø±`¥Î¨ÓºÊ´ú­ý³Ý¯f¤H¤§¯f±¡¡H
A.·ð¤§¶Ý¥ì¬õ²Ó­M¼Æ
B.§K¬Ì³J¥ÕE(lgE)
C.FEV1/FVC
D.¦y®p©I®ð¬y³t(PEFR)
E.Eosinophil Cationic Protein
 
(E) 5.Ų§O¶EÂ_«æ©ÊµÇ¥\¯à´c¤Æ®É±`¥Îªº§¿«ü¼Æ(urine indices)¥H¤U¦C¤¤¦óªÌ³Ì±Ó·P¡H
A.§¿¶u¿@«×
B.§¿¤ñ­«(specific gravity)
C.¦å¤¤BUN/creatinine¤ñ¨Ò
D.§¿º¯³zÀ£(urine osmolality)
E.¶u±Æªn¤ñ¨Ò(fractional excretion of sodium)
 
(E) 6.¨º¤@ºØ¿E¯À»P¨Å©Ðµo¨|µLÃö¡H
A.¥Òª¬¸¢¿E¯À
B.¥Íªø¿E¯À
C.©Ê¿E¯À
D.¯Ø®q¯À
E.¥H¤W¬Ò«D
 
(B) 7.¨Ï¥Î¦åºÞ¤ÉÀ£¯ÀÂà´«úC§í¨î¾¯(ACEI)ªvÀø¿}§¿¯f¯f¤H®É¡A¤U¦C±Ô­z¦óªÌ¥¿½T¡H(1) µÇµ·²yÅ餺¦åÀ£­°§C(2) §¿¤¤¥Õ³J¥Õ±Æªn¶q¼W¥[(3) ¦å¤¤¤T»Ä¥Ìªo¯×¿@«×ª@°ª(4) ³q±`¤£¼vÅT¦å¿}¿@«×(5) ¦å¹[¿@«×­°§C
A.1,2
B.1,4
C.1,5
D.1,3,5
E.1,3,4,5
 
(C) 8.¦b«æ¶E³B¸I¨ì«æ©Êļ¯g(acute mania)ªº±wªÌ¡A¨Ï¥Î¤U¦C¨º¤@ºØÃľ¯¹ïļ¯gªº±±¨î®ÄªG³Ì§Ö¥X²{¡H
A.Carbamazapine (Tegretol)
B.Sulpiride (Dogmatyl)
C.Haloperidol (Haldol)
D.Lithium carbonate (Lithonate)
E.Resperidone (Risperdol)
 
(E) 9.¤U¦C¸£¯Ê¦å©Ê¸£¤¤­·¤Þ°_ªº¯«¸g²Ó­M·l¶Ë¾÷Âत¡A¨º¤@¶µ¬O¿ù»~¡H
A.¦bischemic penumbra¯Ê®ñ±¡ªp¤Uªº¸²µå¿}¥NÁ·|¤Þ°_»Ä¦å¯g(acidosis)
B.¾¢Ói»ÄÆQ(Glutamate)²£¥Í¹L¦h¡A¬O²Ó­M·l¶Ëªº­ì¦]¤§¤@
C.²Ó­M¤ºªº¶tÂ÷¤l¼W¥[¡A¬¡¤Æ³J¥Õ½è»Ã¯À(protease)¡A­P¨Ï²Ó­M·l¶Ë
D.²Ó­M½¤ªº¥h·¥¤Æ(depolarization)¤Þ°_²Ó­M¥\¯à¬¡°Ê´î§C
E.­p¹º©Ê²Ó­M¦º¤`(Apoptosis)¡A¤£·|¦b¸£¤¤­·¯f¨_µo¥Í
 
(D) 10.¤U¦C¨º­Ó²§±`¦å²M­È¡A¥i¥H§@¬°¹w´ú¯T½HµÇª¢µo¥Íªº¦MÀI¦]¤l¡H
A.°ª®Ä»ùªº§Ü®Ö§ÜÅé(ANA)
B.C-reactive protein­È°ª©ó30 mg/dL
C.Anti-SSA/Ro§ÜÅ骺¥X²{
D.¦å²M¸ÉÅé­°§C
E.Ãþ­·Àã¦]¤l(Rheumatoid factor)ª@°ª
 
(D) 11.¤U¦C¦³Ãö¸~½F¼Ð°O¬Û¹ïÀ³ªºÀù¯g¡A¦óªÌ¿ù»~¡H
A.PSA: prostate cancer
B.Calcitionin: medullary cancer of the thyroid
C.CEA: colon, breast or lung cancer
D.CA-125: pancreatic cancer or cholangiocarcinoma
E.Alpha-fetoprotein: hepatocellular carcinoma or germ cell tumor
 
(B) 12.¥¿½Tªº­°À£Ãľ¯ªº¨Ï¥Î¦³¡G1. §Q§¿¾¯¤£À³¦b¥¥°ü¨Ï¥Î2. £\ªýÂ_¾¯(£\-blockers)¥i­P°_¥ß©Ê§C¦åÀ£(orthostatic hypotension)3. £]ªýÂ_¾¯(£]-blockers)¥i­P¯×½è¥NÁ²§±`4. ¶tÂ÷¤l«ú§Ü¾¯(calcium antagonist)¦³§Q°ªÄÖ¯f¤H¤§°ª¦åÀ£5. ACE§í¨î¾¯¥i¦b¥¥°ü¨Ï¥Î
A.1, 2, 3
B.2, 3, 4
C.1, 3, 5
D.2, 4
E.1, 4, 5
 


< ¤K¤Q¤E¦~«×¸ÕÃD¥Ø¿ý >